Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607591 | 1.00 | PDE4A (0.42) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL2122285 | 0.98 | PDE4A (0.41) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL419462 | 0.94 | PDE4A (0.45) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL10738624 | 0.94 | PDE4A (0.45) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL17144674 | 0.94 | PDE4A (0.45) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL18730385 | 0.92 | PDE4A (0.44) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL1537561 | 0.92 | PDE4A (0.44) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL10743488 | 0.92 | TDP1 (0.44) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL8384985 | 0.87 | PDE4A (0.38) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 | |
| SCHEMBL1257816 | 0.84 | LMNA (0.39) | PDE4ALMNAUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282773-B2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEAGEN INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10443035-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190276796-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2019-09-12 | — | — | US | disclosed |
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2018-06-07 | — | — | US | disclosed |
| US-9816069-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20150337259-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2015-11-26 | — | — | US | disclosed |
| US-8993326-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140031536-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2282773-B1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8574907-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120183997-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8163551-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2282773-A2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | Seattle Genetics, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090317869-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009135181-A2 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031536-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | PDE4A 4544/4885LMNA 2329/4885USP2 1994/4885 |
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | PDE4A 4544/4885LMNA 2329/4885USP2 1994/4885 |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | PDE4A 4544/4885LMNA 2329/4885USP2 1994/4885 |
| US-10443035-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | PDE4A 4544/4885LMNA 2329/4885USP2 1994/4885 |
| US-20190276796-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | PDE4A 4544/4885LMNA 2329/4885USP2 1994/4885 |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | PDE4A 4544/4885LMNA 2329/4885USP2 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.